Compare Quanta Services Inc (PWR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quanta Services Inc vs Recursion Pharmaceuticals Inc — how do they compare? Quanta Services Inc trades at $694.26 (market cap $103.03B), while Recursion Pharmaceuticals Inc trades at $4.27 (market cap $2.14B). The key difference: Quanta Services Inc is far larger — about 48.1× Recursion Pharmaceuticals Inc's market cap, and Quanta Services Inc pays a 0.06% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quanta Services Inc for 62 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| PWR | RXRX | |
|---|---|---|
Market Cap | $103.03B | $2.14B |
Volume | 977,892 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $785.24 | $6.79 |
52-Week Low | $412.21 | $2.84 |
Typical Hold Time | 62 Days | 22 Days |
Enterprise Value | $109.13B | $1.66B |
Dividend Yield | 0.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PWR trades at $701.07, down 2.57% on the day, but maintains a bullish technical stance with strong support near $690. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, climbing from $17.1B in 2022 to $28.5B in 2025, though net margins remain modest at 4.03%. Analyst sentiment is overwhelmingly positive, with a consensus price target of $802.08 implying significant upside.
The outlook for PWR is favorable, driven by a record $53B backlog and exposure to AI infrastructure spending. Key risks include execution challenges on large projects and rising debt levels. With 75% of analysts rating it a Buy and strong institutional support, the stock presents a growth opportunity, but investors should monitor cash flow trends and competitive pressures.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
